Press & events

What's happening?

Stay updated on our latest news and events.

Displaying 21 - 30 of 120

Insights

Despite the delay to Brexit, pharmaceutical companies still have limited guidance on the regulatory landscape following the UK’s exit from the European Union (EU).

Insights

When drug products are transferred from the UK to the EU market, they will still need to comply with FMD requirements.

Insights

There are many reasons why oral solid dosage (OSD) forms remain the most popular, including their cost effectiveness, patient-friendly nature and ability to extend product lifecycles by implementing extended, controlled and rapid release formulations.

Insights

Orally inhaled drug products offer many therapeutic advantages over other dosage forms, the primary advantage being a direct delivery to the central nervous system. As such, drug developers can produce delivery strategies that reduce the chances of patients experiencing adverse effects.

Insights

There is a growing interest among drug developers and manufacturers in the use of modified release (MR) oral dosage forms. MR formulations offer formulation scientists and patients many advantages, such as improved efficacy, increased convenience and optimised performance.

Insights

Källsten, M., Pijnappel, M., Hartmann, R. , Lehmann, F., Kovac, L., Bergström Lind, S.  and Bergquist, J Analytical and Bioanalytical Chemistry (2019)

Insights

The United Kingdom (UK) will leave the European Union (EU) on 29th March 2019. The steps and measures pharmaceutical firms take at this stage will be critical to post-Brexit preparedness, failure to take action could ultimately impact the supply of medicines and patient safety.

Insights

The uncertainties surrounding Brexit and the impact it will have on the new EU FMD regulation and wider pharmaceutical industry are growing as the UK’s deadline for leaving the EU draws closer. The UK will have to legally comply with the EU FMD until the 29th March, however insight into what will happen after this date remains limited.

Insights

Geriatrics represent the most important patient population to consider for patient-centric dosage forms.

Insights

Companies striving to become compliant with the FMD must consider a wide range of factors. From selecting the right hardware and software, to training staff and ensuring that their packing lines will not be disrupted, there is a lot to put in place.

It is now unlikely that all companies will achieve compliance on time without halting production.